Carol Goodman, MD
Family Medicine · Evansville, INNPI 1629052386
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $113,854 of the $122,522 with a category attached, or 92.9%. AbbVie accounts for 93.7% of it on its own, with 43 other manufacturers making up the rest. Reporting peaked in 2022 at $73,762 and has fallen 99.6% since, to $271 in 2025. Among family medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 452 payments — averaging $271.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$115K
- Merz North America, Inc.$3K
- GSK$1K
- Novo Nordisk$642
- Amgen$539
- AstraZeneca$260
- plus $2K from 38 others
What the payments were for
- Speaking & faculty fees$113,85493%
- Food & beverage$8,6627%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$122,522 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 49 | $70,752 |
| XareltoRivaroxaban | 44 | $55,052 |
| EliquisApixaban | 38 | $52,520 |
| JardianceEmpagliflozin | 40 | $49,748 |
| TrulicityDulaglutide | 16 | $39,623 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $38,923 |
| FarxigaDapagliflozin Propanediol | 22 | $21,618 |
| JanuviaSitagliptin Phosphate | 20 | $19,626 |
| SynthroidLevothyroxine Sodium | 126 | $11,596 |
| MyrbetriqMirabegron | 24 | $11,345 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $10,265 |
| PremarinEstrogens, Conjugated | 21 | $9,268 |
| TradjentaLinagliptin | 14 | $8,953 |
| Praluent PenAlirocumab | 14 | $7,766 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $6,162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $642 | $70,75249 claims |
| PfizerEliquis, Premarin | $137 | $61,78859 claims |
| Boehringer IngelheimJardiance, Tradjenta | $75 | $58,70254 claims |
| Johnson & JohnsonXarelto | $185 | $55,05244 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,009 | $49,18847 claims |
| Lilly USA, LLCTrulicity | $194 | $39,62316 claims |
| AstraZenecaFarxiga | $260 | $21,61822 claims |
| MerckJanuvia | $209 | $19,62620 claims |
| AbbVieSynthroid | $114,815 | $11,596126 claims |
| Astellas Pharma US IncMyrbetriq | $141 | $11,34524 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $60 | $3,235371 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Evansville
- Anthony InzerelloEvansville$308K
- David SchultzEvansville$22K
- J Christopher SartoreEvansville$19K
- David BrougherEvansville$18K
- Hubert ReyesEvansville$18K
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Joe BanksIndianapolis$294K
- Steven GatewoodElwood$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.